Cellular Biomedicine (CBMG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,208 | -22,069 | -11,407 | -4,210 | -19,448 |
| Depreciation Amortization | 2,635 | 2,034 | 1,349 | 672 | 2,095 |
| Income taxes - deferred | N/A | N/A | -242 | -1,129 | N/A |
| Accounts receivable | 537 | 548 | 275 | 51 | -498 |
| Accounts payable and accrued liabilities | -28 | -33 | -125 | -52 | -196 |
| Other Working Capital | -255 | -716 | -981 | -182 | -1,899 |
| Other Operating Activity | 9,452 | 8,163 | 2,378 | 1,267 | 8,195 |
| Operating Cash Flow | $-15,868 | $-12,072 | $-8,753 | $-3,583 | $-11,751 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,677 | -1,642 | -1,162 | -675 | -1,875 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -1,569 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 2 |
| Purchase Sale Intangibles | -57 | -11 | N/A | N/A | -4,260 |
| Other Investing Activity | -57 | -11 | 0 | 0 | -4,261 |
| Investing Cash Flow | $-2,733 | $-1,653 | $-1,162 | $-675 | $-7,702 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 43,286 | 43,123 | 42,613 | 5,063 | 19,647 |
| Financing Cash Flow | $43,286 | $43,123 | $42,613 | $5,063 | $19,647 |
| Exchange Rate Effect | -317 | -166 | -113 | -23 | -80 |
| Beginning Cash Position | 14,885 | 14,885 | 14,885 | 14,885 | 14,771 |
| End Cash Position | 39,252 | 44,116 | 47,470 | 15,668 | 14,885 |
| Net Cash Flow | $24,368 | $29,231 | $32,586 | $783 | $114 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,868 | -12,072 | -8,753 | -3,583 | -11,751 |
| Capital Expenditure | -2,677 | -1,642 | -1,162 | -675 | -1,875 |
| Free Cash Flow | -18,545 | -13,715 | -9,914 | -4,258 | -13,626 |